Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for NSTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 -0.25M
December 31, 2025 0.00
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.00
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
December 31, 2013 0.00
September 30, 2013 0.00
June 30, 2013 0.0161M
March 31, 2013 0.75M
December 31, 2012 0.0246M
September 30, 2012 0.00
June 30, 2012 0.00
March 31, 2012 0.00
December 31, 2011 0.00
Date Value
September 30, 2011 0.00
June 30, 2011 0.00
March 31, 2011 16.40M
December 31, 2010 0.00
September 30, 2010 0.00
June 30, 2010 0.00
March 31, 2010 0.00
December 31, 2009 0.00
September 30, 2009 0.00
June 30, 2009 0.00
March 31, 2009 0.073M
December 31, 2008 2.125M
September 30, 2008 0.00
June 30, 2008 -0.1229M
March 31, 2008 0.00
December 31, 2007 5.104M
September 30, 2007 -0.03M
June 30, 2007 0.00
March 31, 2007 -0.1738M
December 31, 2006 -0.0226M
September 30, 2006 -0.2829M
June 30, 2006 -0.07M
March 31, 2006 -0.0188M
December 31, 2005 -0.5594M
September 30, 2005 -0.0018M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Brainstorm Cell Therapeutics, Inc. -1.023M
Summit Therapeutics, Inc. -230.57M
Kezar Life Sciences, Inc. -0.267M
Protara Therapeutics, Inc. 0.00
Clene, Inc. -6.405M